AbbVie Inc. (ABBV)

NYSE: ABBV · Real-Time Price · USD
189.28
-1.47 (-0.77%)
At close: Jul 3, 2025, 1:00 PM
189.25
-0.03 (-0.02%)
After-hours: Jul 3, 2025, 5:00 PM EDT
-0.77%
Market Cap 334.34B
Revenue (ttm) 57.37B
Net Income (ttm) 4.16B
Shares Out 1.77B
EPS (ttm) 2.34
PE Ratio 80.89
Forward PE 16.85
Dividend $6.56 (3.47%)
Ex-Dividend Date Jul 15, 2025
Volume 3,706,116
Open 191.15
Previous Close 190.75
Day's Range 188.87 - 191.47
52-Week Range 163.52 - 218.66
Beta 0.48
Analysts Buy
Price Target 213.14 (+12.61%)
Earnings Date Jul 31, 2025

About ABBV

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $213.14, which is an increase of 12.61% from the latest price.

Price Target
$213.14
(12.61% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AbbVie Stock At $190: Premium Pricing For A Transformation Story

AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This o...

1 day ago - Forbes

AbbVie to buy Capstan Therapeutics for up to $2.1 billion

AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.

3 days ago - Reuters

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...

3 days ago - PRNewsWire

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved,  SKINVIVE by JUVÉDERM® wi...

3 days ago - PRNewsWire

AbbVie to Host Second-Quarter 2025 Earnings Conference Call

NORTH CHICAGO, Ill. , June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens.

3 days ago - PRNewsWire

This Changes Everything: One Of The Most Important Shifts For Dividend Investors

Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba...

Other symbols: AMARKKCATCNQEEMEGPELS
3 days ago - Seeking Alpha

Best Dividend Aristocrats For July 2025

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...

Other symbols: ABTADMADPAFLALBAMCRAOS
4 days ago - Seeking Alpha

Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer

The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in em...

8 days ago - GlobeNewsWire

My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys

Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment st...

8 days ago - Seeking Alpha

2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'

Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered di...

Other symbols: BKH
9 days ago - Seeking Alpha

3 dividend stocks investors can look for stability as Iran attacks US base in Qatar

US stocks could see pressure this week after Iran struck US bases in Qatar in retaliation for President Trump's airstrike on Tehran's nuclear facilities. Amidst the geopolitical backdrop that seems to...

Other symbols: KOPG
10 days ago - Invezz

I'm Buying Dividend Giants At Huge Discounts

Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...

Other symbols: BMYCVXOXYPFESHELSLBTTE
13 days ago - Seeking Alpha

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

13 days ago - PRNewsWire

AbbVie's migraine drug meets main goal of late-stage study

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.

15 days ago - Reuters

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migrain...

15 days ago - PRNewsWire

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...

Other symbols: AMGNJNJMRKPFE
16 days ago - CNBC

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow

AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost reven...

16 days ago - Seeking Alpha

AbbVie says blood cancer drug fails late-stage trial

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.

17 days ago - Reuters

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagno...

17 days ago - PRNewsWire

AbbVie: Margin Clarity, Dividend Durability Awaited

AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Pipeline and acquisitions support long-term growth, but macro risks lik...

17 days ago - Seeking Alpha

AbbVie Moves From Blockbuster Loss To Market Domination

Skyrizi and Rinvoq are rapidly replacing Humira, generating over $5 billion in Q1 2025 alone. From migraine to Parkinson's and obesity, AbbVie is building dominant franchises across multiple high-grow...

17 days ago - Seeking Alpha

AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth

AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expec...

18 days ago - Seeking Alpha

AbbVie's Post-Humira Strategy Is Paying Off For Investors

AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from Hum...

18 days ago - Seeking Alpha

Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie

The Investment Committee debate the latest Calls of the Day.

Other symbols: APDNFLXNRG
20 days ago - CNBC Television

Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight

The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibito...

21 days ago - GlobeNewsWire